News |

Alan Irvine, MD, DSc, discusses his Revolutionizing Atopic Dermatitis session and exciting advances in AD.

The promising data on upadacitinib was presented at the 2023 Revolutionizing Vitiligo Virtual Conference

Keep up with the latest headlines in dermatology from the past week, including efficacy of nemolizumab in prurigo nodularis, the addition of a skin bank in northern India where skin banks are scarce, and more.

ICYMI, this week we had articles about upcoming conferences in 2024, the potential causal relationship between pure hypercholesterolemia and psoriasis, the first patient dosed in Kymera's phase 2 AD trial, and more.

This week’s collection of the latest dermatologic studies covers the burden of pediatric AD, skin cancer risk associated with combined methotrexate and NB-UVB therapy in patients with moderate to severe PsO, stigma towards patients with acne, and detection of nonmelanoma skin cancers in Mohs surgical sections using deep learning.

The holidays are a wonderful time to catch up with family members on where the journey of life has taken us during the past year, but they are also a time to share microbiome organisms with others who are genetically similar to us.

As 2023 ends and 2024 approaches, we are thankful for a year dedicated to new therapeutics for patients in need, and we look forward to a new year of continued innovations.

Approximately 76% of patients reported being "satisfied," while 18% reported they were "very satisfied" with treatment.

Investigators explored the genetic relationship between psoriatic disease and serum lipid levels.

Approximately 96.2% of patients had achieved PASI75 by week 12 of the study.

KT-474 is a first-in-class, investigational IRAK4 degrader.

A patient returns to your clinic seeking systemic therapy for her AD while postpartum and breastfeeding. Test your knowledge on injectables.

In this week’s Pointers With Portela, the 208SkinDoc gives his recommendations for a pre-teen skin care routine.

The approval of Galderma’s Restylane Eyelight was one of Martin’s top highlights of 2023.

A 12-year-old patient and their family seeks answers to adjust lifestyle habits and therapies. Test your knowledge on what cytokines can indicate.

Linda Stein Gold, MD, reviewed recent studies of various topical retinoids and their ability to decrease atrophic scars during the 2023 ARM Yourself With Knowledge webinar.

Researchers explored the potential causal relationship between pure hypercholesterolemia, a recognized risk factor for cardiovascular disease, and psoriasis.

Jordan Bui and Bernard A. Cohen, MD, review a case of a young patient with vitiligo.

The study found that alopecia has a significant economic burden on women and their families.

Leading atopic dermatitis experts weigh in on bath routines with different ages, cultures, and more to consult patients and their families.

A woman is trying to conceive and wants to take all steps to prevent her child from inheriting severe atopic dermatitis. Test your knowledge on recommendations.

Baldwin reviewed inflammatory bowel disease, depression, and pregnancy during the 2023 ARM Yourself With Knowledge webinar.

The collaboration, named ARTIBAND, will extend over a 3-year period

DecisionDx-Melanoma significantly influences treatment plans for melanoma patients, as reported by 82.4% of surveyed nurse practitioners and physician assistants.

Investigators used LIMS to classify melanoma samples as tumors and non-tumors.

Click here to answer this week's skin cancer poll.

Zakiya Pressley Rice, MD, took a deep dive into how atopic dermatitis severity and increased rates of grade school absenteeism affect patients with skin of color during a recent Masterclasses in Dermatology meeting.

Understanding these relationships is crucial for developing effective clinical management strategies for patients with AD, according to a recent literature review.

2023 was full of advancements in both medical and cosmetic dermatology, and 2024 is shaping up to be just as exciting.

Ahead of 2024, Dermatology Times wants to know what conferences and meetings you plan to attend in early 2024. Share your thoughts with us by December 10.